@ArarisBiotech profile picture
Araris Biotech @ArarisBiotech

Enabling the development of highly efficient and safe #AntibodyDrugConjugates (ADCs) through our proprietary linker technology.

Joined August 2021
  • Tweets 204
  • Following 98
  • Followers 100
181 Photos and videos
What’s behind the journey of building a platform-driven biotech company? Our CEO, Dragan Grabulovski, sat down with @pharmaboardroom to share his experience as a biotech entrepreneur. Read the full article here: pharmaboardroom.com/intervie… #ADCs #interview #Biotech #ArarisBiotech
1
67
Proud to announce our founding team has won the 2025 Strüngmann Award for breakthrough ADC technology! Thank you for recognizing our mission!💙 globenewswire.com/news-relea…
1
2
118
Our CSO, Philipp Spycher, will speak at the Antibody Industrial Symposium (AIS) on June 25! Tune in for insights on the future of ADCs and biotech innovation. #AIS2025 #ADC #Biotech
0:10
2
49
Araris Biotech is heading to #BIO2025 in Boston (June 16-19)! Meet our team to learn about our ADC pipeline and multi-payload AraLinQ™ technology. DM to connect! #Biotech #ADC #Araris #CancerResearch #ADCs
0:05
93
Our CBO, Filippo Mulinacci, will be attending BIO International in Boston from 16-19 June. Reach out to find out more about our innovative ADC pipeline and multi-payload AraLinQ™ technology. #Araris #BIO2025 #ADCs #conference #networking
1
118
Our CBO, Filippo Mulinacci, sat down with Emma Ulker from @NatureBiotech, to speak about his career so far. Read the full article here: nature.com/articles/d41586-0… #Araris #Interview #Career #Biotech #ADC
59
We are thrilled to announce a research agreement with Johnson & Johnson to develop next-generation antibody drug conjugates (ADCs) using our AraLinQ™ technology. Read the full announcement here: ararisbiotech.com/docs/arari… #Araris #CancerResearch #ADCs #Partnership
1
93
Next week, our co-founder and CTO, Isabella Attinger-Toller, will be presenting our latest next-generation ADC technology developments at the @AACR Annual Meeting 2025 in Chicago! #AACR25 #ADCTherapeutics #CancerResearch #ArarisBiotech #Conference
92
We are pleased to see our innovative antibody conjugation technology featured on the cover of the April issue of ChemBioChem! Read the publication here: chemistry-europe.onlinelibra… #ADC #ChemBioChem #Araris
1
114
We are excited to announce the publication of our latest preclinical data in @AACR’s Molecular Cancer Therapeutics, showcasing the power of our next-generation ADC technology: ararisbiotech.com/docs/25040… #ADCTherapeutics #OncologyInnovation #Biotech #ArarisBiotech
0:15
1
1
146
Excited to join the BioProcess Online Virtual Panel on March 25 to explore the future of ADCs. Register now to learn more about our multi-payload ADC approach: event.on24.com/wcc/r/4858517… #Araris #ADCs #BioProcessOnline

Accelerating ADC Process Development

Tuesday, March 25, 2025 at 11:00 AM Eastern Daylight Time. The rapid advance of ADCs has tested the fine balance between speed to IND and process development that stands up to the rigors of scale-up...

event.on24.com
1
70
Excited to be part of World ADC’s 15th Annual #WorldADC Conference in London on March 3-6. Join us and other industry leaders to learn more about the latest advancements in #ADCTechnology. #Araris #WorldADC #Conference
100
We are pleased to see that our publication in ChemBioChem describing a new technology for developing ADCs that supports our foundational technology platform is currently one of the most read publications in the journal. Read the publication: chemistry-europe.onlinelibra…
126
In @Citeline's latest “Scrip Asks...What Does 2025 Hold For Biopharma?” our CEO, Dragan Grabulovski, shares his insights on the exciting potential of ADCs. Read more here: insights.citeline.com/scrip/… #Biopharma #Araris #DrugDevelopment #ADC

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

insights.citeline.com
1
2
94
On this #WorldCancerDay, we honor all those whose lives have been touched by cancer. We envision a world without chemotherapy and are committed to developing a new generation of #ADCs to tackle the persistent challenges of cancer resistance. #Araris #CancerResearch
0:05
64
We are very excited to announce a major research collaboration and option to license agreement with Chugai Pharmaceutical! ararisbiotech.com/docs/25010… #Araris #ADCs
1
4
3
3,199
Next week our CSO Philipp Spycher will be delivering his keynote presentation, Novel Dual-Payload ADCs That Show Excellent Biophysical Properties and High Efficacy in Vivo, at PEGS Europe on 6 Nov in Barcelona at 14:20 CET. pegsummiteurope.com/engineer…
0:05
1
118
Next Tuesday, the Araris team will be participating at the Festival of Biologics in Basel. If you are attending and would like to connect with Dragan, Philipp or Romain please email: info@ararisbiotech.com #Araris #ADC #Conference
1
1
77
We are pleased to see our innovative approach to multi-payload ADCs featured in @BioProcess Online! Learn more about our efforts to enhance the performance of ADCs and mitigate side effects: Araris Doubles Down With Dual-payload ADC (bioprocessonline.com)
2
75
Our CEO, Dragan Grabulovski, was recently interviewed by Brad Loncar from Biotech TV at our labs near Zurich. Check out the full video: biotechtv.com/post/araris-bi… #ADC #AntibodyDrugConjugates #ADCTechnology #Patents #Agreement

Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of...

Acting CEO Dragan Grabulovski describes how they are able to achieve this, the benefits of having multiple payload classes at once, and the targets the company is currently working on.Zurich based...

biotechtv.com
1
2
93
Load more